BNP Paribas Financial Markets Sells 37,044 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

BNP Paribas Financial Markets decreased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 85.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,252 shares of the specialty pharmaceutical company's stock after selling 37,044 shares during the quarter. BNP Paribas Financial Markets' holdings in KalVista Pharmaceuticals were worth $53,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in KALV. Aquatic Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $44,000. Tower Research Capital LLC TRC boosted its holdings in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 1,494 shares during the last quarter. Martin Worley Group purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after buying an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Stock Up 1.4%

KalVista Pharmaceuticals stock traded up $0.19 during mid-day trading on Wednesday, reaching $13.54. 540,104 shares of the company's stock traded hands, compared to its average volume of 431,120. The company has a market cap of $673.15 million, a price-to-earnings ratio of -3.72 and a beta of 0.05. The stock has a 50 day moving average of $11.93 and a two-hundred day moving average of $10.51. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Analyst Ratings Changes

Several equities analysts have weighed in on KALV shares. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading reaffirmed a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $24.83.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 3,808 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the sale, the chief executive officer now owns 293,367 shares of the company's stock, valued at approximately $3,473,465.28. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the purchase, the insider now owns 5,303,985 shares of the company's stock, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 15,399 shares of company stock valued at $182,054 over the last 90 days. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).